News

December 25th 2019 TAGCyx receives milestone payment for collaborative research with HEALIOS K.K.

TAGCyx is pursuing collaborative research with HEALIOS K.K. (CEO: Hardy TS Kagimoto, MD, Head office: Tokyo, listed on Tokyo Stock Exchange Mothers Index: 4593) to generate innovative DNA aptamers for use in regenerative medicine using TAGCyx’ proprietary Xenoligo® platform. We are pleased to disclose that we have reached a milestone in the collaboration and received the relevant milestone payment.

Due to confidentiality obligations in our agreement with Healios, further details are not disclosed.

Comments are closed.